Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field

作者：Sheila Lumley, Jolynne Mokaya, Tongai Maponga, Anna Kramvis, Geoffrey Dusheiko, William L. Irving, Marion Delphin, Khadija Said Mohammed, Louise Downs, Elizabeth Waddilove, Motswedi Anderson, Collins Iwuji, Nokukhanya Msomi, Ponsiano Ocama, Saeed Hamid, Danjuma Adda, Rachel Halford, Kenneth Kabagambe, Kimberley Benschop, Seth Inzaule, Polin Chan, Margaret Alia Samson Paul, Kiyohiko Izumi, Tiara Nisa, Jean de Dieu Iragena, Amalia Girón‐Callejas, Aboudou Raïmi Kpossou, Ganiyu Jamiyu, Omolara Emmanuel, Mahamadou Balkissa, Mamadou Keïta, Nishi Prabdial-Sing, Alexander A. Martínez, Eleanor Namusoke Magongo, Yiming Shao, Omar Sued, Leandro Soares Sereno, Robert W. Shafer, Olufunmilayo Lesi, Diana Faini, Philippa Easterbrook, Chris Duncombe, Michael R. Jordan, Philippa C. Matthews · 发表于：The Lancet Microbe · 年份：2025 · DOI：10.1016/j.lanmic.2025.101076 · 被引用次数：11 · 研究领域：Hepatitis B Virus Studies、Hepatitis C virus research、Liver Disease Diagnosis and Treatment

In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.